Literature DB >> 32739919

Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients' Response to Biological Therapy and the Need for Colectomy.

Mirko Di Ruscio1, Angela Variola2, Filippo Vernia3, Gianluigi Lunardi4, Paola Castelli5, Paolo Bocus6, Andrea Geccherle2.   

Abstract

BACKGROUND: The main goal in the treatment of ulcerative colitis (UC) is to achieve mucosal healing. Despite being unvalidated, the most widely used scoring system is the Mayo endoscopic subscore (MES). However, the recently established and validated Ulcerative Colitis Endoscopic Index of Severity (UCEIS) represents an interesting alternative method in assessing endoscopic disease activity.
OBJECTIVE: Due to a lack of reliable prognostic factors, the aim of this study was to investigate the diagnostic accuracy of the UCEIS and the MES, in predicting response to biological therapy and the need for colectomy.
METHODS: We conducted a retrospective, uncontrolled, single-center study on UC patients with endoscopically active disease even with concomitant conventional and/or biological therapy, who had already started or had been changed a biological treatment.
RESULTS: Sixty-one UC patients were enrolled. At baseline, 71% were naive to biological therapies and 41% had an extensive colitis. At control time (median time of 11.5 months), MES and UCEIS scores significantly decreased from those at baseline (from 2.6 to 1.8 and 5 to 3.2, respectively, p < 0.001). UCEIS, but not MES, was found to be significantly associated with unresponsiveness to therapy (p = 0.040). Moreover, when UCEIS was ≥7, all patients underwent colectomy after a median time of 5 months (p < 0.001).
CONCLUSION: UCEIS may be superior to MES because of its accuracy and predictive role. Therefore, UCEIS should be considered for use in daily clinical practice.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  (3–5): ulcerative colitis; Endoscopy; Mayo endoscopic subscore; Predictive factors; Ulcerative Colitis Endoscopic Index of Severity

Year:  2020        PMID: 32739919     DOI: 10.1159/000509512

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

1.  [Improved Mayo Endoscopic Score has a higher value for evaluating clinical severity of ulcerative colitis].

Authors:  Z Song; M Zhang; Y Ren; B Iang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-07-20

2.  Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis.

Authors:  Natsuki Ishida; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Dig Dis Sci       Date:  2021-08-30       Impact factor: 3.487

3.  Automated evaluation of colon capsule endoscopic severity of ulcerative colitis using ResNet50.

Authors:  Naoki Higuchi; Hiroto Hiraga; Yoshihiro Sasaki; Noriko Hiraga; Shohei Igarashi; Keisuke Hasui; Kohei Ogasawara; Takato Maeda; Yasuhisa Murai; Tetsuya Tatsuta; Hidezumi Kikuchi; Daisuke Chinda; Tatsuya Mikami; Masashi Matsuzaka; Hirotake Sakuraba; Shinsaku Fukuda
Journal:  PLoS One       Date:  2022-06-10       Impact factor: 3.752

Review 4.  Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores.

Authors:  Bruno Lima Rodrigues; Márcia Carolina Mazzaro; Cristiane Kibune Nagasako; Maria de Lourdes Setsuko Ayrizono; João José Fagundes; Raquel Franco Leal
Journal:  World J Gastrointest Endosc       Date:  2020-12-16

5.  Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis.

Authors:  Xiao-Fei Zhang; Peng Li; Xue-Li Ding; Hao Chen; Shao-Jun Wang; Sheng-Bo Jin; Jing Guo; Zi-Bin Tian
Journal:  Gastroenterol Rep (Oxf)       Date:  2021-07-15

Review 6.  Evolution and New Horizons of Endoscopy in Inflammatory Bowel Diseases.

Authors:  Tommaso Lorenzo Parigi; Elisabetta Mastrorocco; Leonardo Da Rio; Mariangela Allocca; Ferdinando D'Amico; Alessandra Zilli; Gionata Fiorino; Silvio Danese; Federica Furfaro
Journal:  J Clin Med       Date:  2022-02-07       Impact factor: 4.241

Review 7.  How to assess endoscopic disease activity in ulcerative colitis in 2022.

Authors:  Mirko Di Ruscio; Marco Cedola; Manuela Mangone; Stefano Brighi
Journal:  Ann Gastroenterol       Date:  2022-07-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.